17-Alpha-Hydroxyprogesterone Caproate for the Prevention of Preterm Birth in Women With Prior Preterm Birth and a Short Cervical Length

被引:1
|
作者
Berghella, Vincenzo [1 ]
Figueroa, Dana
Szychowski, Jeff M.
Owen, John
Hankins, Gary D. V.
Iams, Jay D.
Sheffield, Jeanne S.
Perez-Delboy, Annette
Wing, Deborah A.
Guzman, Edwin R.
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Obstet & Gynecol, Div Maternal Fetal Med, Philadelphia, PA 19107 USA
关键词
D O I
10.1097/OGX.0b013e3181f07822
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The primary risk factors for recurrent spontaneous preterm birth (SPTB) are a history of SPTB and a short cervical length (CL) found on second trimester transvaginal ultrasound (TVU). In women with prior SPTB or a short CL, the most frequently used interventions to prevent preterm birth (PTB) are cerclage and progesterone supplementation. It is unclear whether the effects of the progesterone agent 17-alpha-hydroxyprogesterone caproate (17P) are additive in women with both primary risk factors. It is also unclear whether 17P is beneficial for women with a prior SPTB and a short CL not undergoing TVU-indicated cerclage. The aim of this study was to evaluate the effect of 17P for the prevention of PTB in pregnant women with prior SPTB, and a short CL, with and without TVU-indicated cerclage. The study was a secondary analysis of a randomized controlled trial sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, evaluating cerclage for singleton women with prior SPTB (17-33 6/7 weeks), and CL < 25 mm between 16 and 22 6/7 weeks. The trial was conducted by 15 US clinical centers from 2003 through 2007. The women available for the final analysis were randomized to cerclage (n = 148) or no cerclage (n = 152). The primary study outcome was the effect of 17P on PTB < 35 weeks' gestation. The cerclage and no-cerclage groups were analyzed separately. The data showed that 17P had no effect on PTB < 35 weeks in women with or without cerclage (P = 0.64; P = 0.51, respectively). The use of 17P in the no-cerclage group significantly lowered the odds of PTB < 24 weeks (odds ratio [OR], 0.08; P = 0.0022) and perinatal death (OR, 0.14; P = 0.0029). These findings suggest that the use of 17P in women with prior SPTB who underwent TVU-indicated cerclage for short CL < 25 mm provides no additive benefit for prevention of PTB < 35 weeks. In women with these primary risk factors who did not receive cerclage, 17P was associated with reduced previable birth and perinatal mortality.
引用
收藏
页码:477 / 478
页数:2
相关论文
共 50 条
  • [21] 17-alpha-hydroxyprogesterone caproate compared to vaginal progesterone for prevention of recurrent spontaneous preterm birth in singleton gestations
    Oler, Elizabeth
    Eke, Ahizechukwu C.
    Hesson, Ashley
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 216 (01) : S181 - S182
  • [22] Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth
    Heyborne, Kent D.
    Allshouse, Amanda A.
    AMERICAN JOURNAL OF PERINATOLOGY, 2016, 33 (12) : 1191 - 1197
  • [23] Rates of recurrent preterm delivery in women receiving 17 alpha-hydroxyprogesterone caproate by gestational age and reason for prior preterm birth
    Istwan, Niki
    Rhea, Debbie
    Desch, Cheryl
    Stanziano, Gary
    Gonzalez-Quintero, Victor Hugo
    Cordova, Yvette C.
    Tudela, Felipe
    Marimon, Adrian
    Romary, Leticia Maria
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2011, 204 : S80 - S81
  • [24] Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth
    Yee, Lynn M.
    Liu, Lilly Y.
    Sakowicz, Allie
    Bolden, Janelle R.
    Miller, Emily S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (03)
  • [25] Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth
    Manuck, Tracy A.
    Esplin, M. Sean
    Biggio, Joseph
    Bukowski, Radek
    Parry, Samuel
    Zhang, Heping
    Huang, Hao
    Varner, Michael W.
    Andrews, William
    Saade, George
    Sadovsky, Yoel
    Reddy, Uma M.
    Ilekis, John
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (03)
  • [26] SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth
    不详
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 223 (01) : B16 - B18
  • [27] Uterine Activity in Women Receiving 17 α-Hydroxyprogesterone Caproate for the Prevention of Preterm Birth: An Observational Study
    O'Brien, John M.
    Ho, Shannon J.
    Istwan, Niki B.
    Stanziano, Gary J.
    Rhea, Debbie J.
    Barton, John R.
    AMERICAN JOURNAL OF PERINATOLOGY, 2010, 27 (02) : 157 - 162
  • [28] Reassessing Preterm Birth Prevention After the Withdrawal of 17-α Hydroxyprogesterone Caproate
    Heyborne, Kent D.
    OBSTETRICS AND GYNECOLOGY, 2023, 142 (03): : 493 - 501
  • [29] 17 α-Hydroxyprogesterone Caproate (Makena®)A Guide to Its Use in the Prevention of Preterm Birth
    Mary Hines
    Katherine A. Lyseng-Williamson
    Emma D. Deeks
    Clinical Drug Investigation, 2013, 33 : 223 - 227
  • [30] Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate
    Durnwald, Celeste P.
    Momirova, Valerija
    Rouse, Dwight J.
    Caritis, Steve N.
    Peaceman, Alan M.
    Sciscione, Anthony
    Varner, Michael W.
    Malone, Fergal D.
    Mercer, Brian M.
    Thorp, John M., Jr.
    Sorokin, Yoram
    Carpenter, Marshall W.
    Lo, Julie
    Ramin, Susan M.
    Harper, Margaret
    Spong, Catherine Y.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2010, 23 (12): : 1360 - 1364